Research Article| Volume 31, ISSUE 2, P272-285, February 2009

Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: A phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study

      This paper is only available as a PDF. To read, Please Download here.


      Background: Risedronate 5 mg/d is approved by the US Food and Drug Administration for the treatment and prevention of postmenopausal osteoporosis. Once-monthly dosing options might increase treatment compliance and persistence.
      Objective: The aim of this study was to compare the tolerability and efficacy of 3 once-monthly risedronate dosing regimens with those of risedronate 5 mg/d.
      Methods: This Phase II, 6-month, randomized, double-blind, active-controlled, dose-ranging study was conducted at 13 clinical research centers and hospitals in Croatia, Poland, Canada, and the United States between April 2004 and June 2005. Post-menopausal women aged 50 to 85 years with a lumbar spine T-score <-2.0 were randomly assigned to 1 of 4 treatment groups: risedronate 100, 150, or 200 mg/mo or 5 mg/d (active control), administered PO for 6 months. Evaluation of tolerability, the primary study objective, was based on adverse-event (AE) profiles and clinical laboratory values. Efficacy evaluation, a secondary objective, was a noninferiority comparison of the changes from baseline in bone mineral density (BMD) and bone turnover markers (BTMs).
      Results: Of 370 patients randomized (91, 88, 88, and 103 patients in the risedronate 100-, 150-, and 200-mg/mo and 5-mg/d groups, respectively), 57% were ≥65 years of age and 99% were white; 316 patients (85.4%) completed the study. Completion rates were not significantly different across treatment groups, nor were reasons for discontinuation. Between-group differences in the incidences of treatment-emergent AEs, serious AEs, and upper gastrointestinal (GI) AEs were nonsignificant. Overall, 6 (7%), 14 (16%), 6 (7%), and 9 patients (9%) withdrew because of AEs in the 100-, 150-, and 200-mg/mo and 5 mg/d groups, respectively. GI disorders were the AEs that most frequently led to study withdrawal (5 [5.5%], 7 [8.0%], 4 [4.5%], and 6 [5.8%]). No trends were observed in the nature or frequency of other AEs causing withdrawal. All serious AEs were considered unrelated to treatment, with the exception of erosive esophagitis in 1 patient (1%) who received the 5-mg/d dose. Mean percentage increases in BMD were 2.10%, 2.99%, and 3.38% with risedronate 100, 150, and 200 mg/mo, respectively, versus 3.05% with 5 mg/d. At the 2 higher monthly doses, the changes from baseline in BMD were not significantly different from those in the 5-mg/d group. Mean BTM values were decreased significantly from baseline in all 4 treatment groups, and the changes from baseline at 6 months at the 2 higher monthly doses were not significantly different from those at 5 mg/d.
      Conclusions: Overall, in this study, the safety profiles of risedronate 100, 150, and 200 mg/mo were not different from that of risedronate 5 mg/d. Changes in efficacy measures in the monthly treatment groups were considered dose related and were not significantly different between the 5-mg/d group and the 150- and 200-mg/mo groups; similarity was greatest with 150 mg/mo.

      Key words:

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. National Osteoporosis Foundation. Osteoporosis fast facts [NOF Web site]

      2. (Accessed February 22, 2008)
      3. National Osteoporosis Foundation. Medications to prevent & treat osteoporosis [NOF Web site]

      4. (Accessed January 13, 2009)
        • Emkey RD
        • Ettinger M
        Improving compliance and persistence with bisphosphonate therapy for osteoporosis.
        Am J Med. 2006; 119: S18-S24
        • Caro JJ
        • Ishak KJ
        • Huybrechts KF
        • et al.
        The impact of compliance with osteoporosis therapy on fracture rates in actual practice.
        Osteoporos Int. 2004; 15: 1003-1008
        • Cramer JA
        • Gold DT
        • Silverman SL
        • Lewiecki EM
        A systematic review of persistence and compliance with bisphosphonates for osteoporosis.
        Osteoporos Int. 2007; 18: 1023-1031
        • Yood RA
        • Emani S
        • Reed JI
        • et al.
        Compliance with pharmacologic therapy for osteoporosis.
        Osteoporos Int. 2003; 14: 965-968
        • Eastell R
        • Garnero P
        • Vrijens B
        • et al.
        Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: The IMPACT study.
        Calcif Tissue Int. 2003; 72 (Abstract P-297): 408
        • Harris ST
        • Watts NB
        • Genant HK
        • et al.
        Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
        JAMA. 1999; 282: 1344-1352
        • Reginster J
        • Minne HW
        • Sorensen OH
        • et al.
        Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.
        Osteoporos Int. 2000; 11: 83-91
        • Brown JP
        • Kendler DL
        • McClung MR
        • et al.
        The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis.
        Calcif Tissue Int. 2002; 71: 103-111
        • Delmas PD
        • Benhamou CL
        • Man Z
        • et al.
        Monthly dosing of 75 mg risedronate on 2 consecutive days a month: Efficacy and safety results.
        Osteoporos Int. 2008; 19: 1039-1045
        • McClung MR
        • Geusens P
        • Miller PD
        • et al.
        • for the Hip Intervention Program Study Group
        Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.
        N Engl J Med. 2001; 344: 333-340
      5. US Dept of Health and Human Services. International Conference on Harmonisation; Guidance on General Considerations for Clinical Trials

      6. (Accessed September 7, 2008)
      7. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects.
        JAMA. 2000; 284: 3043-3045
      8. World Heath Organization. World Health Organization definitions for osteoporosis [WHO Web site]

      9. (Accessed January 13, 2009)
      10. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Medical Dictionary for Regulatory Activities (MedDRA)

      11. (Accessed September 25, 2008)
      12. Burtis CA Ashwood ER Tietz Textbook of Clinical Chemistry. 3rd ed. WB Saunders, Philadelphia, Pa1999
        • Fogelman I
        • Ribot C
        • Smith R
        • et al.
        Risedronate reverses bone loss in postmenopausal women with low bone mass: Results from a multinational, double-blind, placebo-controlled trial BMD-MN Study Group.
        J Clin Endocrinol Metab. 2000; 85: 1895-1900
        • Snedecor GW
        • Cochran WG
        Statistical Methods. 8th ed. Iowa State University Press, Ames, Iowa1989: 374-397
        • Cohen S
        • Levy RM
        • Keller M
        • et al.
        Risedronate therapy prevents corticosteroid-induced bone loss: A twelve-month, multicenter, randomized, double-blind, placebo- controlled, parallel-group study.
        Arthritis Rheum. 1999; 42: 2309-2318
        • Reid DM
        • Hughes RA
        • Laan RF
        • et al.
        Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study.
        J Bone Miner Res. 2000; 15: 1006-1013
        • Hooper MJ
        • Ebeling PR
        • Roberts AP
        • et al.
        Risedronate prevents bone loss in early postmenopausal women: A prospective randomized, placebo-controlled trial.
        Climacteric. 2005; 8: 251-262
        • Singer FR
        • Clemens TL
        • Eusebio RA
        • Bekker PJ
        Risedronate, a highly effective oral agent in the treatment of patients with severe Paget's disease.
        J Clin Endocrinol Metab. 1998; 83: 1906-1910
        • Hosking DJ
        • Eusebio RA
        • Chines AA
        Paget's disease of bone: Reduction of disease activity with oral risedronate.
        Bone. 1998; 22: 51-55
        • Miller PD
        • Brown JP
        • Siris ES
        • et al.
        A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group.
        Am J Med. 1999; 106: 513-520
        • Siris ES
        • Chines AA
        • Altman RD
        • et al.
        Risedronate in the treatment of Paget's disease of bone: An open label, multicenter study.
        J Bone Miner Res. 1998; 13: 1032-1038
        • Brown JP
        • Hosking DJ
        • Ste-Marie L
        • et al.
        Risedronate, a highly effective, short-term oral treatment for Paget's disease: A dose-response study.
        Calcif Tissue Int. 1999; 64: 93-99
        • Racewicz AJ
        • Schofield PJ
        • Cahall DL
        • et al.
        Monthly dosing with risedronate 50 mg on three consecutive days a month compared with daily dosing with risedronate 5 mg: A 6-month pilot study.
        Curr Med Res Opin. 2007; 23: 3079-3089
        • Roux C
        • Seeman E
        • Eastell R
        • et al.
        Efficacy of risedronate on clinical vertebral fractures within six months.
        Curr Med Res Opin. 2004; 20: 433-439
        • Harrington JT
        • Ste-Marie LG
        • Brandi ML
        • et al.
        Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis.
        Calcif Tissue Int. 2004; 74: 129-135